Dolutegravir Tetra-O-acetyl- O-Beta-D-glucoside

Ref. TR-D528830

Informação sobre produto

• Nome: Dolutegravir Tetra-O-acetyl- O-Beta-D-glucoside
• Sinónimos: (2R,3R,5R,6S)-2-(Acetoxymethyl)-6-(((4R,12aS)-9-((2,4-difluorobenzyl)carbamoyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate

Descrição

Applications Dolutegravir Tetra-O-acetyl- O-β-D-glucoside is an intermediate in the synthesis of Dolutegravir O-β-D-Glucoside (D528815) which is a metabolite of Dolutegravir (D528800); a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.
References Kobayashi, M. et al. Antimicrob Agents Chemother., 55, 813 (2011); Garrido, C. et al.: Antiviral, Res., 90, 164 (2011); Lenz, J.C.C. et al.: Exp. Opin. Invest. Drugs, 20, 537 (2011)

• Marca: TRC

Propriedades químicas

• Peso molecular: 749.67
• Fórmula: C₃₄H₃₇F₂N₃O₁₄
• Cor/forma: Pale Brown Foam
• InChI: InChI=1S/C34H37F2N3O14/c1-15-8-9-47-25-13-38-12-22(32(45)37-11-20-6-7-21(35)10-23(20)36)27(44)29(26(38)33(46)39(15)25)53-34-31(51-19(5)43)30(50-18(4)42)28(49-17(3)41)24(52-34)14-48-16(2)40/h6-7,10,12,15,24-25,28,30-31,34H,8-9,11,13-14H2,1-5H3,(H,37,45)/t15-,24-,25+,28-,30?,31-,34+/m1/s1
• Chave InChI: InChIKey=XSQUCXPUDIKVPN-WZQOJGDESA-N
• SMILES: CC(=O)OC[C@H]1O[C@@H](Oc2c3n(cc(C(=O)NCc4ccc(F)cc4F)c2=O)C[C@@H]2OCC[C@@H](C)N2C3=O)[C@H](OC(C)=O)C(OC(C)=O)[C@@H]1OC(C)=O